Mesoblast Ltd (ASX: MSB) Share Price and News

Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. Dr Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies. He is the member of the Clinical Committee Member.

Dr Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he checked development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr Rose played a role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). He is the member of the Clinical Committee Member.

Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F Hoffmann La Roche Ltd until he retired in 2014. Mr Burns is also a member of the Oncology Advisory Board of the Universities of Cologne/ Bonn in Germany. He is the member of the Clinical Committee Member.

Ms Bell is an experienced Chair and non-executive Director in regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. She is a former Chair of Royal Melbourne Hospital and former Chair of Biomedical Research Victoria as well as Chair of Advisory Groups for the Royal Australian and New Zealand College of Obstetricians and Melbourne Genomics Health Alliance, a former director of Hudson Institute of Medical Research and director of U Ethical, Australia's first ethical funds manager. Ms Bell is a Member of the Order of Australia (AM), appointed for her service to governance in the medical research, healthcare and not-for-profit sectors. She is the member of the risk committee.

Mr Facchina has more than 35 years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Prior to SurgCenter, he spent two decades in the public and private capital markets, where he directly managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take-privates. Mr Facchina led the technology, media, and communications and healthcare investment banking groups of FBR Capital Markets. He is the member of the risk commmittee.

Dr Krause has a combination of scientific, regulatory, clinical, and public health experience. He is currently an independent consultant, providing strategic and regulatory advice related to biological product development. Dr Krause has a strategic advisory consulting role with Mesoblast, providing advice on regulatory strategies. He is the member of the Clinical Committee Member.

Ms Cobley brings over 35 years'executive experience in senior positions at Australian and Global banks with experience in P&L leadership, risk management, equity and debt capital markets, balance sheet management, strategy and leadership, people and culture matters, technology, cybersecurity and navigating complexity in regulated industries. She is the member of the risk committee.

Dr George identified the necessity for surgeons to have more control over their daily schedule, surgical time, operating room protocols, and surgical staffing. He is the chairperson of the Clinical Committee Chair.

-

-

-

-